Company description

Cayman Pharma is the world’s most reliable source of prostaglandin Active Pharmaceutical Ingredients (APIs) using its own patented route to manufacture APIs for erectile dysfunction, ophthalmic, veterinary, and vascular applications.  Cayman Pharma has an excellent track record with over 30 years of experience and an outstanding record of regulatory compliance.

Cayman Pharma was formed in October of 2006 by the merger of two companies with very different geographic origins. Both, however, had unparalleled experience and expertise in Prostaglandin Chemistry. One was Cayman Chemical, a research biochemical company with global recognition as an expert in the field of lipid chemistry. The other was NeraPharm, a company located within the Spolana complex north of Prague since the late 1970s, but only operating as an independent legal entity since 2002. NeraPharm was conceived during the era of Soviet economic domination and central planning. Their goal, which was largely achieved, was to implement independent production of important veterinary prostaglandins for the entire Eastern Bloc. Cayman had its beginnings just a few years later, in 1980. Cayman's vision, also largely accomplished, was to demonstrate that naturally occurring prostaglandins from corals could be an economical and versatile raw material. Targeting the research community instead of the human and veterinary market, Cayman was soon selling a wide variety of extremely pure and valuable prostaglandin standards.

Cayman Pharma represents the joining of almost 60 years of experience with prostaglandin synthesis and biochemistry. NeraPharm brings to the new company a deep understanding of GMP manufacturing under US FDA and EMEA standards, and many years of experience supplying pharmaceutical grade active ingredients. The Czech company also provides Cayman with a tremendous boost in manufacturing capacity. Cayman, on the other hand, brings cutting edge knowledge both in the research field and in GMP methods for the most advanced prostaglandin compounds. Drug candidates for newer indications such as glaucoma, male and female sexual dysfunction, and pulmonary hypertension are all part of the Cayman portfolio.

Cayman Pharma will strive to make the best possible use of its joint EU and US GMP manufacturing operations to ensure that the prostaglandin API that the customer needs is properly certified and ready for release.

Quick facts

Primary business activity Manufacturer
Affiliated categories: Prostaglandins More

Upcoming events

13 oct 2020

CPhI Worldwide 2020

13 - 15 October 2020 Milan, Italy Visit us at stand 16B80 Book a meeting See our Exhibitor Profile   See full Exhibitor List

Recently at

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany We were at stand 40A41 See our Exhibitor Profile   See full Exhibitor List
21 aug 2019

CPhI Korea 2019

21-23 August 2019 Seoul, Korea We were at stand D15 See our Exhibitor Profile   See full Exhibitor List

Categories affiliated with Cayman Pharma s.r.o

Cayman Pharma s.r.o

Contact information




View all contact information